バキュロウイルスが誘導する即効性自然免疫応答による
肝臓期マラリア原虫の殺傷効果

**Baculovirus-inducing fast-acting innate immunity
kills *Plasmodium* liver stages**

Talha Bin Emran

Dissertation

Baculovirus-inducing fast-acting innate immunity kills *Plasmodium* liver stages

Graduate School of Medical Sciences

Kanazawa University

Division: Pharmaceutical Sciences

Laboratory: Vaccinology & Applied Immunology

School Registration No.   : 1529012008

Name   : Talha Bin Emran

Primary Supervisor Name   : Prof. Shigeto Yoshida

SUMMARY

Malaria is a life-threatening disease cause 216 million cases worldwide and almost 445,000 deaths every year. *Plasmodium* sporozoite parasites injected by a female *Anopheles* mosquito, travel to the liver and infect hepatocytes, afterward the clinical phase of malaria infection occurred in blood stage. The liver-stage parasites asymptomatically produce thousands of merozoites that will subsequently infect erythrocytes. Therefore, an effective innate immune response raised before or during the liver-stage infection could prevent the onset of disease. *Autographa californica* nucleopolyhedrosis virus (AcNPV), a type of Baculovirus (BV), is an enveloped insect virus with a circular double-stranded DNA genome, possesses unique characteristics to induce strong innate immune responses in various mammalian cells and in mice. The aim of my study was to assess the capability of the BV-induced innate immune responses for protecting mice against malaria pre-erythrocytic stage along with its adjuvant properties.

Here I show that the innate immune responses induced by BV not only eliminate *Plasmodium* liver-stage parasites but also elicit sterile protection against *Plasmodium* sporozoite infection through type I interferon (IFN) signaling pathway. Mice had infected with liver-stage parasites before 24 h completely prevented blood-stage parasites following single dose of BV intramuscular administration, which was much superior to primaquine (PQ), the only drug approved to eradicate liver-stage parasites indicating an excellent therapeutic effect as well as the short-term prophylactic effect. This BV-mediated liver-stage parasite elimination was also observed in *TLR9$^{-/-}$* mice. In addition to the therapeutic effect, BV intramuscular administration sterilely protects mice for at least seven days from subsequence sporozoite infection, indicating the prophylactic effect. At 6 h post-BV administration, IFN-α and IFN-γ were robustly produced in the sera, and RNA transcripts of interferon-stimulated genes were drastically upregulated in the liver compared with control mice. The in vivo passive transfer with sera from mice intramuscularly administered with BV effectively eliminated liver-stage parasites and this effect was canceled by neutralization of IFN-α but not IFN-γ in the sera, indicating a killing mechanism downstream of type I IFN signaling pathway. In conclusion, my results provide a great potential of BV for development of BV-based vaccine and anti-hypnozoite drug as a new stand-alone therapeutic and prophylactic immunostimulatory agent with a killing mechanism downstream of type I IFN signaling pathway, which is applicable not only for malaria but also for other serious infectious diseases such as viral hepatitis and liver cancers.

LIST OF CONTENTS

ABBREVIATIONS

Ab	antibody
AcNPV	*Autographa californica* nucleopolyhedrosis virus
AdHu5	human adenovirus type 5
AdHu5-luc	recombinant AdHu5 expressing luciferase
Ag	antigen
ALT	alanine aminotransferase / alanine transaminase
ANOVA	analysis of variance
AST	aspartate aminotransferase / aspartate transaminase
BDES	baculovirus dual-expression system
BES	baculovirus expression system
BV	baculovirus
CpG	a cytosine-guanine dinucleotide, p indicates the phosphate bond
CSP	cirucumsporozoite protein
DC	dendritic cell
DAF	decay-accelerating factor
DAI	DNA-dependent activator of IFN-regulatory factors
dsDNA	double stranded deoxyribonucleic acid
EGFP	enhanced green fluorescent protein
ELISA	enzyme-linked immunosorbent assay
G6PD	glucose-6-phosphate-dehydrogenase enzyme
IFNAR	interferon-α/β receptor
IFNGR	interferon-gamma receptor
IFN	interferon
IFITs	IFN-induced proteins with tetratricopeptide repeat
ILs	interleukins
i.m.	intramuscular
i.n.	intranasal
i.p.	intraperitoneal
IRF	interferon-regulatory factor
ISGs	interferon stimulated genes
IVIS	in vivo imaging system
i.v.	intravenous

KO	knockout
NK	natural killer cell
NKT	natural killer T-cell
OAS	$2'$-$5'$ oligoadenylate-synthetase
ODN	oligodeoxynucleotides
PAMPs	pathogen-associated molecular patterns
PCR	polymerase chain reaction
PBS	phosphate-buffered saline
Pb-conGFP	transgenic *P. berghei* ANKA parasite line that constitutively express GFP
Pb-luc	transgenic *P. berghei* ANKA parasite line that constitutively express luciferase
pCMV	cytomegalovirus immediate early promoter
PfCSP-Tc/Pb	transgenic *P. berghei* ANKA parasite line that express *P. falciparum* CSP under the control of the *P. berghei* CSP promoter
pfu	plaque-forming unit
p.i.	post-infection
PKR	protein kinase R
pPolh	polyhedron promoter
pRBC	parasitized red blood cell
PRRs	pattern recognition receptors
PQ	primaquine
qRT-PCR	real-time quantitative reverse transcription polymerase chain reaction
RNaseL	ribonuclease L
RLU	relative luminescence units
SEM	standard error mean
Spz	sporozoites
TLR	toll-like receptor
TNF	tumor necrosis factor
VLP	virus like particle
VSV-G	vesicular stomatitis virus G glycoprotein
WHO	World Health Organization
WT	wild type

INTRODUCTION

Malaria remains a severe public health problem and causes significant economic losses worldwide. In 2016, there were approximately 216 million malaria cases and an estimated 445,000 malaria deaths, mainly in children under five years age (1). Malaria infection is initiated following injection of *Plasmodium* sporozoites injected into the skin during the taking of a blood meal by *Anopheles* mosquitoes. The sporozoites then migrate to the liver and invade hepatocytes. Before clinical symptoms of malaria occur during the blood stage of infection, *Plasmodium falciparum* in the liver develops into exoerythrocytic schizonts for 5 to 6 days. *Plasmodium vivax* and *Plasmodium ovale* can develop dormant liver-stage forms, known as hypnozoites, which cause relapsing blood-stage infections months or years after the primary infection. The clinically silent pre-erythrocytic stages of mammalian *Plasmodium* spp, composed of both the sporozoite and liver stages represent the first opportunity the mammalian host has to mount a defense against *Plasmodium* infection (2). Moreover, the liver-stage development compensates for the low numbers of transmitted sporozoites, a major bottleneck of the *Plasmodium* life cycle. Therefore, the pre-erythrocytic stages are deal targets for both the vaccine interventions and prophylactic drug discovery (2).

Currently, the only licensed drug for the radical cure of *P. vivax* hypnozoites is artemisinin-based combination therapies and primaquine (PQ) which are recommended by the World Health Organization (WHO) as the first-line treatment for blood-stage *P. falciparum* malaria. Artemisinin-based combination therapies (ACTs) are recommended by WHO as the first-line treatment for uncomplicated *Plasmodium falciparum* malaria. However, artemisinin resistance has emerged in Southeast Asia, (3) and possible ACT-resistant *P. falciparum* malaria cases have been reported in Sub-Saharan Africa (4). Therefore, the WHO advocates increased monitoring and surveillance to identify and contain artemisinin resistance (5). For drug development against the liver-stage parasite, currently, the only licensed drug for the radical cure of *P. vivax* malaria is primaquine (PQ), which kills liver stage parasites, including hypnozoites (6). But, PQ has a high associated risk of life-threatening hemolytic anemia in people with glucose-6-phosphate-dehydrogenase enzyme (G6PD) deficiency (8). For future malaria eradication strategies, safer radical curative compounds that efficiently kill hypnozoites are required. The absence of a fully efficacious vaccine and continuous emergence of drug-resistant parasites pose a serious threat of malaria resurgence. Hence, to control the spread of malaria, development of a safe and fully efficacious control strategies is an urgent priority (5, 7).

A series of studies performed by Nussenzweig and colleagues in 1986-1987 revealed that exogenously administered IFN-γ effectively inhibits the development of liver-stage parasites in vitro and in vivo (8-11). Recently, Boonhok *et al.* reported that IFN-γ-mediated inhibition occurs at least partially in an autophagy-related protein-dependent manner in infected hepatocytes (12). Additionally, Liehl *et al.* reported that hepatocytes infected with wild type (WT) liver-stage parasites induce type I IFN secretion via host cell sensing of *Plasmodium* RNA, resulting in a reduction of the liver-stage burden (13). These findings suggest that IFN-mediated immunotherapy against liver-stage parasites might be effective. However, new anti-hypnozoite drugs (e.g. rIFNs or appropriate IFN inducers) have not been developed yet.

Autographa californica nucleopolyhedrosis virus (AcNPV), a type of baculovirus (BV), is an enveloped, double-stranded DNA virus that naturally infects insects. BVs possess unique characteristics that activate dendritic cell (DC)-mediated innate immunity through both MyD88/Toll-like receptor 9 (TLR9)-dependent and -independent pathways (14). Takaku and colleagues reported that BV also directly activates murine natural killer (NK)-cells through the TLR9 signalling pathway (15, 16), which leads to the induction of NK cell-dependent anti-tumour immunity. With the outstanding adjuvant properties on maturation of DC and activation of NK cells, BV has recently emerged as a new vaccine vector with several other attractive attributes, including (i) low cytotoxicity, (ii) an inability to replicate in mammalian cells, and (iii) an absence of preexisting antibodies. Our lab has developed BV-based malaria vaccines effective for all three parasite stages, the pre-erythrocytic stage (17-19), asexual blood stage (20, 21), and sexual stage (22, 23).

Here, I investigated BV-mediated innate immunity against the pre-erythrocytic stage parasites. My results clearly demonstrate that BV intramuscular administration not only elicits short-term sterile protection against *Plasmodium* sporozoite infection but also eliminates liver-stage parasites completely through the type I IFN signalling pathway. I propose that, due to its potent IFN-inducing characteristics, BV has the potential to be developed not only as a new malaria vaccine additive capable of protecting vaccine recipients for a short period before and after malaria infection but also as a new non-haemolytic single-dose drug.

AIMS OF THE STUDY

BV is an enveloped insect virus with a circular double-stranded DNA genome, possesses unique characteristics to induce strong innate immune responses in various mammalian cells and in mice. Stimulation of innate immune system is a prerequisite for generating robust and long-lasting adaptive immune responses. Immune potentiators (e.g., TLR agonists or cytokines) function by activating innate immune responses, leading to enhanced antigen presentation. Therefore, an effective innate immune response raised before or during the liver-stage infection could prevent the onset of disease.

The overall aim of this thesis was to examine the characteristics features of BV with activation of innate immunity. In the long run, I was chasing against the malaria pre-erythrocytic stage by exploiting the adjuvant properties of baculoviral vector.

In addition, the specific aims of the study were:
- To investigate whether BV-mediated innate immunity could protect animals against malaria challenge infection.
- To study whether BV-mediated innate immunity could eliminate the existing liver-stage parasites.
- To assess whether BV possessed more prophylactic effectiveness than CpG.
- To evaluate whether BV possessed better therapeutic effectiveness than PQ.
- To identify the role of TLR9 in BV-mediated liver-stage parasite elimination.
- To check the interferon's (IFNs) dependent killing mechanism.
- To determine the association of interferon stimulated genes (ISGs) in the killing of liver-stage parasites.

MATERIALS AND METHODS

Animals and cell lines

Female inbred BALB/c (H-2^d) mice were obtained from Japan SLC (Hamamatsu, Shizuoka, Japan) and used in all experiments at 7-8 weeks of age. TLR9-deficient ($TLR9^{-/-}$) mice on a BALB/c background were kindly provided by Shizuo Akira (University of Osaka, Suita, Japan). *Spodoptera frugiperda* (Sf9) and HepG2 cells were maintained as according to the standard protocol (18). Mice were anesthetized with ketamine (100 mg/kg; intramuscular; Daiichi Sankyo, Tokyo, Japan) and xylazine (10 mg/kg; intramuscular; Bayer, Tokyo, Japan) when necessary.

Parasites and mosquitoes

The *Anopheles stephensi* mosquito strain SDA 500 was maintained at the Kanazawa University according to a standard protocol (17, 24). Three transgenic *P. berghei* ANKA parasites were used in this my study: green fluorescent protein (GFP)-*P. berghei* (Pb-conGFP) (25), luciferase-*P. berghei* (Pb-Luc) (26), and *P. falciparum* cirucumsporozoite (PfCSP)-*P. berghei* (PfCSP-Tc/Pb) (27). Transgenic PfCSP-Tcell (Tc)/Pb parasites were generated to replace the PbCSP gene with PfCSP^{A361E} using the same method as described previously (27, 28). These transgenic parasites were maintained by cyclical passaging through BALB/c mice and *A. stephensi* (SDA 500 strain) at the Kanazawa University and Jichi Medical University according to a standard protocol (17, 24).

Parasite production and sporozoite collection

Transgenic parasites used to challenge mice were produced at the insectary of Laboratory of Vaccinology & Applied Immunology, Kanazawa University. *A. stephensi* mosquitoes (SDA 500 strain) were infected either with Pb-conGFP, Pb-Luc, or PfCSP-Tc/Pb by allowing them to feed on parasite-infected mice. The condition of the parasites (in terms of their infectivity) to recipient mice was checked by exflagellation tests before blood feeding commenced. Mosquitoes were exposed to anaesthetized infected mice for 10-30 minutes. Mosquitoes were then maintained for 21 days in a humidified incubator at a temperature of 19–21 °C on a 12-hour day-night cycle and fed with a fructose/PABA solution. On day 18 to 21 after infection, the salivary glands of the mosquitoes were collected by hand-dissection. The mosquitoes used for challenge had salivary gland sporozoite infection rates of 60 to 90%

at 18 to 21 days after the infectious blood meal. Salivary glands were collected in DMEM (Thermo Fisher Scientific K.K., Tokyo, Japan) or RPMI-1640 media (Gibco, Life technologies) and homogenized by a plastic homogenizer. The free sporozoites were counted in haemocytometer (C-Chip, NanoEnTek) counting chamber using phase-contrast microscopy.

Recombinant viruses

The recombinant BVs BES-GL3 and BDES-sPfCSP2-WPRE-Spider have been described previously (29). Recombinant baculovirus, BES-GL3-Spider was designed to express the luciferase gene under the control of the pCMV single promoter, which also contains a gene cassette for hDAF display as described previously (17, 20). Purification of viral particles was performed as described previously (17). The purified BV particles were free of endotoxin (<0.01 endotoxin units/10^9 PFU), as determined by the Endospecy® endotoxin measurement kit (Seikagaku Co., Tokyo, Japan). The recombinant adenovirus, AdHu5-Luc was designed to express the luciferase gene under the control of the CAG promoter, as described earlier (18). To generate the human type 5 adenoviral vector AdHu5-sPfCSP2, the gene cassette encoding the GPI-anchor lacking PfCSP (Leu19-Val367) fused to VSV-G protein membrane anchor sequence with followed by a *wpre* sequence was excised from pFast-sPfCSP2-WPRE-Spider (30) by digestion with *Eco*RI and *Xho*I and then inserted into the *Eco*RI and *Xho*I sites of pAd/PL-DEST (Invitrogen, Carlsbad, CA, USA) under the control of CAG promoter sequences. Purification and titration of adenovirus were carried out using fast-trap adenovirus purification and concentration kits (Millipore, Temecula, CA, USA) and Adeno-X™ Rapid Titer Kit (Clontech, Palo Alto, CA), respectively, according to the manufacturer's protocols. In this thesis, BDES-sPfCSP2-WPRE-Spider and AdHu5-sPfCSP2 are described as BDES-PfCSP and AdHu5-PfCSP, respectively.

Analysis of protective effects against sporozoite parasites

BALB/c mice were intravenously, intramuscularly, or intranasally administered 10^4–10^8 plaque forming units (pfu) of BES-GL3. Alternatively, instead of BES-GL3, BALB/c mice were intramuscularly injected with 50 µg of CpG ODN 1826 (TCCATgACgTTCCTgACgTT, Fasmac Inc., Tokyo, Japan). The mice were intravenously challenged with 1,000 Pb-conGFP sporozoites or 1,000 blood-stage parasite-infected red blood cells at various time intervals (6 h–14 days). The mice were checked for *P. berghei* blood-stage infection by microscopic examination of Giemsa-stained thin smears of their tail

blood, prepared on days 5, 6, 7, 8, 11, and 14 post-challenge. The time required to reach 1% parasitaemia was determined as described previously (31). A minimum of 20 fields (magnification: 1,000×) were examined before a mouse was deemed to be negative for infection. The percentage of parasitaemia was calculated as follows: parasitaemia (%) = [(number of infected erythrocytes)/(total number of erythrocytes counted)] × 100. Protection was defined as the complete absence of blood-stage parasitaemia on day 14 post-challenge.

Analysis of elimination effects on liver-stage parasites

BALB/c mice were intravenously injected with 1,000 Pb-conGFP sporozoites and then intravenously (10^7 pfu) or intramuscularly (10^8 pfu) injected with BES-GL3 at various time intervals (6, 24, or 42 h post-infection). Alternatively, instead of BV, a single high (2 mg) or low (0.1 mg) dose of PQ (primaquine diphosphate 98%, Sigma-Aldrich, St. Louis, MO, USA), with corresponding concentrations of roughly 100 mg/kg body weight and 5 mg/kg body weight respectively, was intraperitoneally administered 24 h after the injection of 1,000 Pb-conGFP sporozoites. The mice were checked for *P. berghei* blood-stage infection and evaluated for 1% parasitaemia as described above.

In vivo bioluminescent imaging

Luciferase activity in mice was visualized through imaging of whole bodies using in vivo imaging system, IVIS (PerkinElmer, Waltham, MA, USA) as described previously (32-34). BALB/c mice were intravenously or intramuscularly injected with BES-GL3 on day 0, and D-luciferin (15 mg/ml; OZ Biosciences, Marseille, France) was then intraperitoneally administered (150 μl/mouse) to these mice at various timepoints. The animals were anesthetized with a ketamine (100 mg/kg)/xylazine (10 mg/kg) mixture 10 min later, and the luciferase expression was detected with an in vivo imaging system, IVIS® Lumina LT in vivo imaging system (PerkinElmer, Waltham, MA, USA). Alternatively, BALB/c mice were intravenously injected with 1,000 Pb-Luc sporozoites followed 24 or 42 h later by intramuscular administration of BES-GL3 (10^8 pfu) into the left thigh muscle. At 72 h after the sporozoite injection, the luciferase expression was detected as described above. At days 5-14 post-infection, the same mice were analysed for blood-stage infections by determination of the course of parasitaemia in Giemsa-stained thin blood films of tail blood.

Cytokine ELISA

BALB/c mice were intravenously or intramuscularly injected with BV, and serum samples were subsequently harvested from whole blood obtained by cardiopuncture at various times and stored at −20 °C until analysis. The concentrations of cytokines in the sera were determined by sandwich ELISA using a Mouse IFN-γ ELISA MAX™ standard kit (Biolegend Inc., San Diego, CA, USA), mouse IL-12/IL-23 (p40) ELISA MAX™ standard kit (Biolegend Inc.), or mouse TNF-α ELISA MAX™ deluxe kit (Biolegend Inc.) according to the manufacturer's instructions. Briefly, ninety-six-well plates (Corning Inc.; Corning, NY, USA) was coated with the capture Ab (100 µl, 1:200), diluted in coating buffer (8.4 g NaHCO$_3$, 3.56 g Na$_2$CO$_3$ in 1L DI H$_2$O, pH 9.5) for overnight at 4 °C. After washing four times with PBS containing 0.05% Tween 20 (200 µl, washing buffer) and blocking with PBS containing 1% BSA (200 µl, assay diluent) for 1 h at room temperature. After washing the plates four times in ELISA washing buffer, diluted samples (in assay diluent) of either sera or cytokine standards were dispensed in duplicate (100 µl/well) and the plates incubated for at 37 °C for 2 h. Standards were serially diluted with assay diluent according to manufacturer's protocol. The plates were then washed as before and added detector mouse biotinylated cytokine (IFN-γ, TNF-α, and IL-12) at dilutions of 1:200 (100 µl/well). This was followed by incubation at 37 °C for 1 h, and washed as before. Streptavidin horseradish peroxidase (SA-HRP; Sigma, USA) diluted 1:1000 in assay diluent was added 100 µl/well and incubated at 37 °C for 30 min before a further six washes. Color development was achieved by adding 100 µl/well of tetramethylbenzidene (TMB) substrate solution A : B in equal proportion (1:1). After incubating for 30 min at room temperature, the optical density was measured at 450 and 570 nm on a multiskan bichromatic microplate reader (Thermo Lab systems, Vantaa, Finland) following the addition of 100 µl of stop solution (1 N H$_2$SO$_4$). IFN-γ, TNF-α, and IL-12 concentration was calculated using a standard curve according to kit protocol.

The IFN-α concentration was determined by sandwich ELISA as described previously (13). In brief, rat monoclonal antibody against mouse IFN-α (clone RMMA-1; PBL Biomedical Laboratories Piscataway, NJ, USA) was used as the capture antibody (2 µg/ml for coating), rabbit polyclonal antibody against mouse IFN-α (PBL Biomedical Laboratories) was used at 80 neutralizing units per ml for detection, and HRP-conjugated goat anti-rabbit IgG (Bio-Rad Laboratories, Hercules, CA, USA) was used as the secondary reagent. Recombinant mouse IFN-α (PBL Biomedical Laboratories) was used as the standard. The lower detection limits for the IFN-γ and IFN-α immunoassays were each <20 pg/ml, whereas those for the IL-12 and TNF-α immunoassays were each <10 pg/ml.

Aspartate transaminase (AST) and alanine transaminase (ALT) assays

Serum samples from intravenously or intramuscularly injected mice with BV were collected at various times by cardiopuncture method and stored at −20 °C until analysis. The levels of alanine transaminase (ALT/GPT) and aspartate transaminase (AST/GOT) from the sera were determined by using a GPT/GOT assay kit (Transaminase CII-test; Wako Pure Chemical Industries, Ltd., Japan), according to manufacturer's instruction. The manufacturer's instructions were precisely followed.

Serum transfer and IFN administration analysis

Pooled sera were obtained from blood harvested by cardiopuncture from five BALB/c mice that had been intramuscularly injected 6 h previously (at −6 h) with BES-GL3, and the concentrations of IFN-α and IFN-γ were measured immediately. On the same day, the IFN-α and IFN-γ in 100 μl aliquots of the pooled sera were neutralized by incubation on ice for 6 h with anti-IFN-α (anti-mouse interferon alpha, rabbit serum; PBL Biomedical Laboratories) and anti-IFN-γ (Ultra-LEAF^{TM} purified anti-mouse IFN-γ antibody; Biolegend Inc.) antibodies, respectively, according to the manufacturer's instructions. At 24 h after being intravenously injected with 1,000 Pb-conGFP sporozoites, BALB/c mice were subsequently intravenously injected with 100 μl of the sera that had been treated with either anti-IFN-α or anti-IFN-γ. For the IFN administration experiment, BALB/c mice that had been intravenously injected with 1,000 Pb-conGFP sporozoites 24 h before were then intravenously administered either 8,619 pg of IFN-α or 4,705 pg of IFN-γ. For each experiment, the mice were checked for *P. berghei* blood-stage infection and evaluated for 1% parasitaemia as described above.

RNA isolation from livers and qRT-PCR quantification

BALB/c (WT or *TLR9$^{-/-}$*) mice were intramuscularly injected with 10^8 pfu of BES-GL3. Alternatively, 50 μg of CpG ODN 1826 were administered intramuscularly. Six hours later, whole livers were obtained by dissection of the treated mice. Each whole liver was placed in a 5-ml plastic tube with a cap containing 4 ml of buffer RLT (Qiagen, Valencia, CA, USA) containing 1% 2-mercaptoethanol. Two stainless steel beads (5-mm external diameter) were added to the mixture. Once the tube was capped, it was attached to a μT-12 Beads Crusher (TAITEC, Saitama Japan), and vigorously shaken at 2,500 rpm for 3.5 min. Total RNA was isolated from 100-μl aliquots of the homogenates by using an RNeasy kit (Qiagen). cDNA was synthesized by using random hexamers and Multiscribe reverse transcriptase (Applied Biosystems, Foster City, CA, USA). Quantitative analysis of RNA

transcripts was performed by Real-time PCR with SYBR® Green Premix Ex Taq™ (Takara, Tokyo, Japan) and the following primer sets:

gapdh (F: TGCCCCCATGTTTGTGATG, R: TGTGGTCATGAGCCCTTCC),

mx1 (F: AACCCTGCTACCTTTCAA, R: AAGCATCGTTTTCTCTATTTC),

oas1a (F: ACTCCTTTGTGGCTCAGTGG, R: ACCAGCTCCACGTCTGTAGTG),

oas1b (F: TTCTACGCCAATCTCATCAGTG, R: GGTCCCCCAGCTTCTCCTTAC),

oasl1 (F: ATGTTAATACTTCCAGCAAGC, R: GCAAAGACAGTGAGCAACTCT),

pkr (F: GATGGAAAATCCCGAACAAGGAG, R: AGGCCCAAAGCAAAGATGTCCAC),

ifit1 (F: CCTTTACAGCAACCATGGGAGA, R: GCAGCTTCCATGTGAAGTGAC),

ifit3 (F: CTGAACTGCTCAGCCCACAC, R: TGGACATACTTCCTTCCCTGA),

ifit44 (F: TCGATTCCATGAAACCAATCAC, R: CAAATGCAGAATGCCATGTTTT),

irf3 (F: GATGGCTGACTTTGGCATCT, R: ACCGGAAATTCCTCTTCCAG),

irf7 (F: CTTCAGCACTTTCTTCCGAGA, R: TGTAGTGTGGTGACCCTTGC).

Amplification of *gapdh* was performed in each experiment. The Ct value of each sample was standardized based on the *gapdh* Ct value (ΔCt), and each ΔCt value was normalized to that of the ΔCt value from PBS-treated control WT mice (ΔΔCt). Results are shown as the relative expression (1/2ΔΔCt).

Protective efficacy of heterologous human adenovirus serotype 5 (AdHu5)-prime/BV dual expression system (BDES)-boost immunization against sporozoite challenge

Recombinant viruses expressing PfCSP, AdHu5-PfCSP, or BDES-PfCSP have been described previously (19, 29). BALB/c mice were first intramuscularly immunized with AdHu5-PfCSP (5×10^7 pfu). After 3 weeks, the mice were intravenously challenged with 1,000 PfCSP-Tc/Pb sporozoites, and, after 24 h, the mice were then intramuscularly immunized either with BDES-PfCSP (1×10^8 pfu) or PBS. The mice were checked for *P. berghei* blood-stage infection and evaluated for 1% parasitaemia as described above. Protected mice were intravenously re-challenged with 1,000 PfCSP-Tc/Pb sporozoites, and protection was defined as described above.


Statistical analysis

Details concerning the study outline, sample size, and statistical analysis are shown in the main text, figures, and figure legends. A two-tailed Fisher's exact probability test was performed to determine the significance of differences in the protective efficacies of the vaccines, using SPSS software (version 19, Chicago, IL, USA). In all other experiments,

statistical differences between the experimental groups were analysed by the methods described in the individual figure legends; p values of <0.05 were considered statistically significant. Statistical analyses were performed with either Prism version 7.0a (GraphPad Software Inc., La Jolla, CA, USA) or Microsoft® Excel (Redmond, WA, USA).

RESULTS

Construction of recombinant BV

Construction of BES-GL3 Spider (BV) is shown in Figure 1. I used the BV called BES-GL3, which harbours two gene cassettes consisting of the *luciferase* gene under the control of the *CMV* immediate-early enhancer-promoter (pCMViep) promoter and the *decay accelerating factor (DAF)* gene under the control of the *p10* promoter. The gene encoding EGFP was driven invertedly by the polyhedrin promoter (pPolh). BES-GL3 was designed to express luciferase as a transducing marker and to display *DAF* as protection for BV from complement attack, respectively (29).

Figure 1: Schematic representation of the luciferase-expressing BV. BES-GL3 Spider vectors express firefly luciferase GL3 under the pCMV promoter and contain a gene cassette for *DAF* display. S, gp64 signal sequence; and EGFP, enhanced green fluorescent protein.

BV administration induces transgene expression and innate immune responses

BV is a promising gene therapy vector capable of transducing broad range of mammalian cells in vitro with significant efficiency leading to stable gene expression (35, 36). BES-GL3 intramuscular administration into the left thigh muscle of mice initially increased the luciferase expression levels robustly, but these levels gradually decreased to 2% on day 28 (Figure 2A), which is consistent with findings from previous studies (29, 37). Among the various cell types tested in vitro, hepatocytes were found to be the most effective at taking up BV (38), suggesting a potential use for BV as a vector for liver-directed gene transfer. However, direct evidence of in vivo liver-directed gene transfer has not been

reported previously because BV-mediated gene transfer into hepatocytes via intravenous injection is severely hampered by serum complement (39). Here, use of our complement-resistant DAF-shielded BES-GL3 revealed for the first time that intravenously administered BV effectively transduces hepatocytes in vivo (Figure 2B).

Figure 2: Transgene expression and innate immune responses after BV administration via intravenous or intramuscular routes. (A, B) Luciferase expression at different timepoints after intramuscular (10^8 pfu) **(A)** or intravenous (10^7 pfu) **(B)** administration of luciferase-expressing BES-GL3 (described as BV), detected by using the IVIS® Lumina LT in vivo imaging system. The heatmap visible in each mouse image represents the total flux of photons (p/sec/cm^2) in that area. Rainbow scales are expressed in radiance (p/s/cm^2/sr).

BV-mediated innate immune responses reject re-administration of BV

To examine antigen expression in vivo, I monitored luciferase expression in the mice by bioluminescence imaging on days 0, 1, 5, and 14 post-intramuscular injections of BV into the left anterior muscle of BALB/c mice (Figure 3A-D). We have previously shown that luciferase expression levels in intramuscular route were gradually reduced over time but detection of luminescence is achievable up to day 11 (29). BV might induce innate immune

responses at the injection site or systemic immunity for more than 10 days, which is consistent with findings from previous studies (29). Moreover, intravenous administration of BES-GL3 initially increased the luciferase expression levels robustly, but the levels gradually decreased to 0% on the day 3 (Figure 3E-G), which is also stable with previous studies (33). Interestingly, when BV-Luc was intramuscularly re-administrated into the left tibialis anterior muscle at day 14, the luciferase expression was not detectable (Figure 3H). The result indicates that BV intravenous administration strongly induces innate immune responses which systemically clear upon the re-administration of BV.

Figure 3: Effects of BV administration. Luciferase expression at different time points after intramuscular (10^8 pfu) (**A-D**) or intravenous (10^7 pfu) (**E-G**) administration of BES-GL3 (BV) detected by using the IVIS® Lumina LT *in vivo* imaging system. After 14 days intravenous BV administration mice were re-administered with BES-Luc (10^8 pfu) by intramuscular route. The expression of luciferase was monitored on day 15 (14+1) post-BV administration (**H**). (**A-H**) The heat map images visible in the mice represent the total flux of photons (p/s/cm^2) in that area.

Recombinant BV induces inflammatory cytokines in both WT and *TLR9*[-/-] mice

Baculovirus virions displaying PbCSP administration was reported to elicit specific antibodies and gamma interferon (IFN-γ) and conferred protection against *P. berghei* challenge infection (40). Since IFN-γ is a critical component of antimalarial liver stage protective response (41), I examined the serum kinetics of proinflammatory cytokines following BES-GL3 intravenous administration. To explore the cellular immune responses, I first determined the Th1-type (IFN-γ and TNF-α) cytokine levels at various times (0, 3, 6, 9, 12, 24, and 48 h) after BES-GL3 intravenous administration. IFN-γ and TNF-α levels rapidly reached their peaks at 6 h and decreased to baseline by 24 h (Figure 4).

Figure 4: Kinetics of proinflammatory cytokines (IFN-γ and TNF-α). Kinetics of proinflammatory cytokines, IFN-γ (**A**) and TNF-α (**B**) in the sera at different timepoints post-BV intravenous administration (10^7 pfu) (n = 6). Line graph shows the increment of the cytokines level with time.

I also compared different cytokines (IFN-γ and TNF-α) production at 6 h after post-BES-GL3 administration by intravenous and intramuscular routes (Figure 5A, B). Intravenous routes robustly produced both Th1-type cytokines levels compare with intramuscular route. In particular, IFN-γ and TNF-α level detected from sera of mice immunized with BES-GL3 by intravenous route was highly significant compared with control ($p < 0.0001$). On the other hand, intravenously administered mice with Ad-Luc and PBS did not induce any significant proinflammatory cytokines.

Figure 5: Comparison between different routes of BV-administration in terms of cytokine production. Levels of IFN-γ (**A**) and TNF-α (**B**) in the sera from WT mice 6 h after intramuscular and intravenous administration of BES-GL3 (described as BV) (10^8 pfu), Ad-Luc (10^{10} pfu), or PBS (n = 6). Bars show the means ± SD. The difference from the PBS group was assessed by a one-way ANOVA with Dunn's correction. ****$p < 0.0001$. i.m., intramuscular; i.v., intravenous.

CpG ODNs are known to induce IFN-γ secretion in previous studies (42). Gramzinski *et al*., reported that, IFN-γ might be involved in the CpG-induced protection against sporozoite challenge (43). As a positive control, less amount of IFN-γ was detected from 6 h intramuscular CpG ODN 1826 (50 μg) sera compare with BV (Figure 6A). The possible reason might be the B-type CpG ODNs which has a complete phosphorothioate backbone and induce the production of modest levels of IFN-α, with much weaker NK cell activation thus lower IFN-γ secretion (44).

BV is known to activate bone marrow-derived dendritic cells to induce the expression of activated cell-surface markers and to produce various kinds of cytokines (IL-6, IL-12p70, and TNF-α) (45). Since IL-12 has been implicated with a role in CpG ODN-induced immunity in other systems (46), so I compared the serum IL-12 levels 6 h post-BV intramuscular administration in WT mice (Figure 6B). Consistent with previous findings (43), CpG intramuscular administration induced a robust IL-12 response than BV administered sera. Results suggested that a strong inflammatory response with a complex pattern of inflammatory cytokines might contribute to the intrinsic immunogenic properties of the administered BV.

Figure 6: Comparison between 6 h post-CpG ODN and BV-administration in terms of cytokine production in WT mice. Levels of IFN-γ (**A**) and IL-12 (**B**) in the sera from WT mice 6 h after intramuscular and intravenous administration of BES-GL3 (described as BV) (10^8 pfu), CpG ODN (50 μg), or PBS (n = 6-15). Bars show the means ± SD. The difference from the PBS group was assessed by a one-way ANOVA with Dunn's correction. *$p < 0.05$, ****$p < 0.0001$. i.m., intramuscular; i.v., intravenous.

To further investigate, I proceeded in *TLR9*$^{-/-}$ mice model for detection of different cytokines (IFN-γ and IL-12) production at 6 h after intramuscular administration of BES-GL3 (Figure 7A, B). Significant amount IFN-γ was detected in both the *TLR9*$^{-/-}$ and WT mice. In particular, IFN-γ level detected from sera of *TLR9*$^{-/-}$ mice immunized with BES-GL3-Spider by intramuscular route was highly significant compared with *TLR9*$^{-/-}$ control group mice ($p < 0.0001$). In contrast, less amount of IL-12 was detected in both *TLR9*$^{-/-}$ and WT group which is not statistically significant with control.

**Figure 7: Recombinant baculovirus induces inflammatory cytokines in *TLR9⁻ᐟ⁻*
mice.** Levels of IFN-γ (**A**) and IL-12 (**B**) in the sera from *TLR9⁻ᐟ⁻* mice 6 h after
intramuscular administration of BES-GL3 (described as BV) (10^8 pfu) or PBS (n = 6-
15). Bars show the means ± SD. The difference from the PBS group was assessed by a
one-way ANOVA with Dunn's correction. ***p < 0.001, ****p < 0.0001, ns, not
significant.

Intravenous BV-administration cause liver injury

     Since previous study suggest that CD8[+] T cell-mediated immune pathology occurs in
the brain but not the liver, while parasite-dependent pathology occurs in both organs during
P. berghei ANKA infection (47). Although BES-GL3 can completely eliminate the liver-
stage parasites, I was interested in liver damages caused by the BES-GL3 administration
through different routes. To evaluate the liver damage, I first examined the serum kinetics of
ALT and AST following BES-GL3 intravenous administration. The ALT and AST levels
each rapidly reached their peaks at 12 h and decreased to baseline by 48 h (Figure 8).

Figure 8: Kinetics of liver damage markers (ALT and AST). Kinetics of liver damage markers, ALT (**A**) and AST (**B**), in the sera at different timepoints post-BV intravenous administration (10^7 pfu) (n = 6). Line graph shows the increment of the enzymes level with time.

I also measured liver damage markers levels after 6 h of BES-GL3 administration through different routes. Compared with intravenous administration, intramuscular administration did not affect the ALT levels; although the AST level trended higher following intramuscular administration, this difference did not reach statistical significance (Figure 9A-C). ALT is a sensitive indicator of liver damage (48), so these results suggest that, for BV, intramuscular administration may be less destructive than intravenous administration. Alternatively, if desired, intravenous administration can induce stronger systemic innate immune responses than intramuscular, depending upon target diseases such as cancers.

Figure 9: Comparison between different routes of BV-administration in terms of liver enzymes. Comparison of ALT (**A**), AST (**B**), and both (**C**) values in the sera at 6 h after intramuscular (10^8 pfu) or intravenous (10^7 pfu) administration of BV (n = 6). Bars or points show the mean ± SD. The difference from the PBS group was assessed by a Kruskal-Wallis test with Dunn's correction. ***$p < 0.001$. i.m., intramuscular; i.v., intravenous.

BV administration elicits sterile protection against sporozoite

Table 1 summarizes the protective efficacy results for BV administration against malaria sporozoite challenge. First, to examine the effects of BV intravenous administration, mice were intravenously administered 10^7 pfu of BES-GL3. At 6 h post-BV injection, which coincides with peak IFN-γ production, the mice were intravenously challenged by 1,000 Pb-conGFP sporozoites, which are transgenic *P. berghei* constitutively expressing GFP. All BV-injected mice were protected, whereas all PBS- and AdHu5-injected mice treated similarly became infected. Next, I investigated the effects of BES-GL3 intramuscular administration (10^8 pfu) followed by sporozoite challenge at various intervals post-BV injection. After intramuscular administration of BES-GL3, all mice were protected for at least 7 days. However, there was a complete loss of protection by 14 days post-BES-GL3 intramuscular

administration and no delay of parasitaemia was observed in these mice. Additionally, no protection was observed in mice treated intranasally with BES-GL3.

BES-GL3 intravenous administration failed to provide protection against challenge with 1,000 parasitized red blood cells (pRBCs) at 6 h post-BV injection, indicating that BV has no residual effect on blood-stage parasites. CpG intramuscular administration at 6 or 24 h prior to challenge conferred protection against sporozoite challenge in 90% or 80% of mice, respectively. This is consistent with previous work showing short-term (2-days) protection induced by CpG intramuscular administration (50 µg) against challenge with 100 *P. yoelii* sporozoites (43), although only partial protection (50%) was observed when the challenge occurred at 7 days post-CpG intramuscular injection. Thus, the protective efficacy induced by BES-GL3 intramuscular administration is more effective and longer-lasting (7-days) compared with that induced by CpG. All PBS-treated control mice developed blood-stage infection within 6 days following an intravenous injection of 1,000 Pb-conGFP sporozoites.

Table 1. Protective efficacy of BV injection against *P. berghei* sporozoite challenge[a, b]

Treatment[a]	Dose (Route[c])	Time interval of challenge after administration	%Protection (protection/total)[d]
PBS	(i.v.)	6 h	0 (0/8)[e]
BV	1×10^7 pfu (i.v.)	6 h	100 (8/8)
AdHu5-luc[f]	5×10^7 pfu (i.v.)	6 h	0 (0/3)
PBS	(i.m.)	12 h – 14 days	0 (0/20)[e]
BV	1×10^8 pfu (i.m.)	12 h	100 (5/5)
BV	1×10^8 pfu (i.m.)	24 h	100 (5/5)
BV	1×10^8 pfu (i.m.)	3 d	100 (5/5)
BV	1×10^8 pfu (i.m.)	5 d	100 (5/5)
BV	1×10^8 pfu (i.m.)	7 d	100 (5/5)
BV	1×10^8 pfu (i.m.)	14 d	0 (0/5)
BV	1×10^8 pfu (i.n.)	6 h	0 (0/3)
BV	1×10^7 pfu (i.v.)	6 h/1,000 pRBC[g]	0 (0/5)
CpG[h]	50 µg (i.m.)	6 h	90 (9/10)[e]
CpG[h]	50 µg (i.m.)	24 h	80 (4/5)

[a]BALB/c mice were injected with BES-GL3 (described as BV) by the indicated route. After the indicated interval, mice were intravenously challenged with 1,000 Pb-conGFP

sporozoites. Parasitaemia was monitored on days 5-8, 11, and 14 after sporozoite challenge. Once parasites appeared in the blood, all mice died.

[b]Scheme of the experimental design is shown in Figure 19A.

[c]i.v., intravenous; i.n., intranasal; i.m., intramuscular.

[d]Protection is defined as the complete absence of blood-stage parasitaemia on day 14 post-challenge.

[e]Cumulative data from two or four experiments.

[f]BALB/c mice were intravenously injected with AdHu5-luc.

[g]BALB/c mice were intravenously challenged with 1,000 Pb-conGFP-pRBC.

[h]BALB/c mice were intramuscularly administered with 50 µg of CpG ODN 1826 (described as CpG).

BV administration completely eliminates of liver-stage parasites

Pathways stimulated by type I and II IFNs can lead to the killing of hepatocytes infected with liver-stage parasites (8-13). Because BV is a potent inducer of type I and II IFNs (45, 49), and I observed BV-mediated protection in Table 1, so in my next experiment I investigated whether BV-induced IFNs could kill liver-stage parasites in vivo. To examine the elimination effects on the trophozoite and exoerythrocytic (mature) schizont stages, I administered BES-GL3 intravenously or intramuscularly at two different intervals following sporozoite challenge, 24 and 42 h, respectively. Table 2 summarizes these results on the elimination efficacy of BES-GL3 administration against liver-stage parasites. Blood-stage parasites were completely prevented in all mice that had been intravenously injected with BES-GL3 at 24 h post-infection; in contrast, the protective effectiveness of BES-GL3 intravenous administration was diminished when mice received it at 42 h post-infection instead. The same results were obtained when mice were intramuscularly injected with BES-GL3.

As PQ is the only licensed drug for the radical cure of *P. vivax* hypnozoites, I also compared the elimination effects of BV with those of PQ. Two different doses of PQ, high dose (2 mg/mouse) and low dose (0.1 mg/mouse), were intraperitoneally administered. A single administration of high dose of PQ completely eliminated the liver-stage parasites (Table 2), whereas a single low dose of PQ was unable to reduce liver parasite burden but caused a significant delay of parasitaemia (Figure 11). The WHO-recommended treatment schedule for PQ is 15 mg/day for 14 days, but because high doses of PQ often cause side

effects like nausea, vomiting, and stomach cramps, these side effects can limit patient compliance, potentially resulting in PQ resistance (50, 51). Thus, BV intramuscular administration may have important advantages of over PQ.

Table 2. Elimination of liver-stage parasites by BV administration[a, b]

Treatment[a]	Dose (Route[c])	Time interval of administration after challenge	%Elimination (uninfected/total)
PBS	(i.v.)	24 h	0 (0/12)[e]
BV	1×10^7 pfu (i.v.)	24 h	100 (13/13)[e]
BV	1×10^7 pfu (i.v.)	42 h	0 (0/3)
PBS	(i.m.)	24 h	0 (0/9)[e]
BV	1×10^8 pfu (i.m.)	24 h	100 (7/7)
BV	1×10^6 pfu (i.m.)	24 h	0 (0/5)[f]
BV	1×10^4 pfu (i.m.)	24 h	0 (0/5)[f]
BV	1×10^8 pfu (i.m.)	42 h	0 (0/3)[f]
PQ (High)[d]	2 mg (i.p.)	24 h	100 (5/5)
PQ (Low)[d]	0.1 mg (i.p.)	24 h	0 (0/5)[f]

[a]BALB/c mice were intravenously injected with 1,000 Pb-conGFP sporozoites. After the indicated interval, mice were administrated either with BES-GL3 (described as BV) or PQ. Parasitaemia was monitored on days 5-8, 11, and 14 after sporozoite injection. Once parasites appeared in the blood, all mice died.

[b]Scheme of the experimental design is shown in Figure 19B.

[c]i.v., intravenous; i.m., intramuscular; i.p., intraperitoneal.

[d]The two different doses of PQ as High (2 mg/100 µl) and Low (0.1 mg/100 µl) were administrated to eliminate liver-stage parasites.

[e]Cumulative data from three experiments.

[f]Significant delay of parasitaemia was observed in infected mice, compared with the PBS group as showing in Figure 11 and 12.

Detection of liver stage parasites elimination by in vivo imaging system

Our group generated a transgenic rodent malaria parasite (*P. berghei*) that consist of the luciferase gene under a promoter region of elongation factor-1α (33). The transgenic parasites designated Pb-Luc expressed luciferase in all stages of their life cycle. To visualize the parasite elimination by BV, mice were infected with Pb-Luc, which are transgenic *P. berghei* constitutively expressing luciferase, and then examined via IVIS; this is a highly sensitive method for detecting liver- and blood-stage parasites. Parasites were observed in the liver at both 24 h and 42 h post-infection (Figure 10A and B, respectively; left panels). BES-GL3 intramuscular administration into the left thigh muscle at 24 h post-infection completely eliminated the liver-stage parasites completely at 72 h post-infection, whereas the PBS control treatment failed to prevent the development of blood-stage parasites (Figure 10A; right panel). Although BES-GL3 intramuscular administration into the right thigh muscle at 42 h post-infection also failed to prevent the development of blood-stage parasites (Figure 10B; right panel), it caused a significant delay of parasitaemia (Figure 11). The exoerythrocytic merozoites of *P. berghei* are released from infected hepatocytes into the blood stream at 44–48 h after the liver stage (52) Therefore, this result indicates that even for exoerythrocytic schizonts (42 h post-infection), the elimination effect of BV intramuscular administration was invoked in the liver within 2–6 h.

Figure 10: Effect of BV intramuscular administration on liver-stage parasites (**A, B**). Mice were challenged by infection with Pb-Luc sporozoites at 0 h, followed by intramuscular administration of BES-GL3 (10^8 pfu; described as BV) at the indicated timepoints. Luminescence in the liver indicates parasite growth, whereas that in the thigh shows the transgene expression by intramuscular BV injection. The heatmap visible in each mouse image represents the total flux of photons (p/s/cm^2) in that area. Rainbow scales are expressed in radiance (p/s/cm^2/sr).

BV possesses great prophylactic efficiency than CpG and primaquine

Next, I investigated whether BV possessed high prophylactic and therapeutic effectiveness than CpG and primaquine, respectively. Intramuscular administration of BES-GL3 into the left thigh muscle at 24 h post-infection completely eliminated the liver-stage parasites at 72 h post-infection as mentioned before. While 42 h post-infection failed to prevent the development of blood-stage parasites but still caused a significant delay of parasitaemia (Figure 11). Results suggested that 42 h post-infection is too late to eliminate the liver-stage parasites and innate immunity induced by BES-GL3-Spider is not effective for

blood-stage parasites. A single administration of high dose PQ completely eliminated the liver-stage parasites whereas a single low dose of PQ was suboptimal, producing only a reduction in parasite burden in the liver and caused a significant delay of parasitaemia (Figure 11). It was conventional that, pretreatment of mice with CpG ODN 1826 provided complete protection from infection when the CpG ODN 1826 was administered 1 or 2 days prior to *P. yoelii* sporozoites challenge (43). Consistent with the previous findings, CpG has a little effect on mature schizonts (24 h post-infection) as it caused a significant delay of parasitaemia (Figure 11). Results implicated that BV has an important potential for anti-liver stage drug.


Figure 11: Comparison among BV, CpG, and primaquine in the elimination of liver stage parasites. Delay of parasitaemia in infected mice. Parasitaemia of the groups of infected mice shown in Table 2 (10^8 pfu of BV injected intramuscularly at 42 h post-infection, and PQ low dose administered at 24 h post-infection), and Table 3 (CpG administered 24 h post-infection). Bars or points indicate the mean ± SD. The difference from the PBS group was assessed by a two-way ANOVA. $*p < 0.05$, $**p < 0.01$, $****p < 0.0001$.

Liver stage parasites elimination efficacy is dependent on dose of BV

Lower doses (10^4 and 10^6 pfu) of BES-GL3 administered at 24 h post-infection failed to prevent blood-stage parasites. However, a significant delay of parasitaemia was observed for the dose of 10^6 pfu of BES-GL3 (Figure 12), indicating that the elimination effect is

dependent on the amount of BV that is intramuscularly administered. From the dose dependent study, I can conclude that 10^8 pfu BES-GL3-Spider dose is the best for the complete elimination of malaria parasites.

Figure 12: Dose dependency of BV on liver stage parasite elimination. Delay of parasitaemia in infected mice. Parasitaemia of groups of infected mice shown in Table 2 (10^6 or 10^4 pfu of BV injected intramuscularly 24 h post-infection). Bars or points indicate the mean ± SD. The difference from the PBS group was assessed by a two-way ANOVA. **$p < 0.01$.

BV-mediated liver-stage parasite killing occurs through TLR9-independent pathways

CpG intramuscular administration completely eliminated early liver-stage parasites completely at 6 h post-infection (Table 3); however, although this treatment caused a significant delay of parasitaemia, it had little effect on mature schizonts (24 h post-infection) as mentioned in Figure 11. BV possesses unique characteristics that activate DC-mediated innate immunity through MyD88/TLR9-dependent and -independent pathways (14). Therefore, next I investigated whether TLR9 plays an important role in BV-mediated parasite killing in the liver. A single dose of intramuscularly administered BES-GL3 completely prevented blood-stage parasites in all *TLR9*[-/-] mice that had been previously infected with liver-stage parasites. In contrast, no elimination effect or parasitaemia delay was observed in

TLR9[-/-] mice following intramuscular administration of CpG (50 µg) (Table 3). These results clearly demonstrate that BV-mediated parasite killing occurs via TLR9-independent pathways.

Table 3. Elimination of liver-stage parasites by BV injection in *TLR9*[-/-] mice[a]

| Treatment[a]	Mouse strain	Dose	Time interval of administration after challenge	%Elimination (uninfected/total)
PBS	*TLR9*[-/-]	-	24 h	0 (0/7)
BV	*TLR9*[-/-]	1×10^8 pfu	24 h	100 (7/7)
BV	WT	1×10^8 pfu	24 h	100 (5/5)
CpG	WT	50 µg	6 h	100 (5/5)
CpG	WT	50 µg	24 h	0 (0/4)[b]
CpG	*TLR9*[-/-]	50 µg	24 h	0 (0/5)

[a]*TLR9*[-/-] (BALB/c background) or WT mice were intravenously injected with 1,000 Pb-conGFP sporozoites. After 24 h, mice were intramuscularly administrated either with BES-GL3 (described as BV) or CpG ODN 1826 (described as CpG). Parasitaemia was monitored on days 5-8, 11, and 14 after sporozoite injection. Once parasites appeared in the blood, all mice died.

[b]Significant delay of parasitaemia was observed in infected mice, compared with the PBS group as shown in Figure 11.

Intramuscular BV administration rapidly induces type I and II IFNs in sera

BV intravenous administration was reported to produce type I IFNs through TLR-independent and IRF3-dependent pathways in mice (14). To further investigate IFN production following BV intramuscular administration, the IFN serum levels were measured in WT and *TLR9*[-/-] mice at 6 h after BES-GL3 intramuscular administration. As with intravenous administration, intramuscular administration of BES-GL3 produced IFN-α in not only WT mice (6,311 ± 2,363 pg/ml) but also *TLR9*[-/-] mice (1,590 ± 737 pg/ml), whilst mice intramuscularly injected with PBS or CpG did not produce detectable IFN-α (< 20.0 pg/ml) (Figure 13A). IFN-γ, a type II IFN was also produced in both WT mice (1,367 ± 1,303 pg/ml) and *TLR9*[-/-] mice (488 ± 132 pg/ml) following intramuscular administration of BES-GL3 (Figure 13B). Compared with BV, CpG intramuscular administration in WT mice induced much less IFN-γ but much more IL-12 (Figure 13C). Notably, CpG intravenous administration induced a high level of IFN-γ with considerable systemic side effects (53, 54).

These results indicate that BES-GL3 intramuscular administration induces production of both type I and II IFN via TLR9-independent pathways.


Figure 13: BV intramuscular administration BV administration rapidly induces type I and II IFNs in sera. (**A-C**) Levels of IFN-α (**A**), IFN-γ (**B**), and IL-12 (**C**) in sera from WT or *TLR9$^{-/-}$* mice at 6 h after intramuscular administration of BES-GL3 (described as BV) (10^8 pfu), CpG, or PBS (n = 9-10). Bars show means ± SD. The difference from the PBS group was assessed by a Kruskal-Wallis test with Dunn's correction. $**p < 0.01$, $****p < 0.0001$.

Liver-stage parasites are killed by IFN-mediated immunity

To determine whether the serum cytokines act as effectors against liver-stage parasites, a serum transfer assay was performed. Pooled sera were collected from donor mice at 6 h after they had been intramuscularly injected with BES-GL3 or PBS. An aliquot of the pooled sera (100 μl/animal) was transferred to each recipient mouse at 24 h after their intravenous injection with 1,000 sporozoites. One of the five recipient mice effectively eliminated the liver-stage parasites, and the other four infected recipient mice showed a significant delay in

the time to 1% parasitaemia (mean delay of 3.54 days; $p = 0.0008$, compared with the PBS sera group) (Figure 14A).

Next I examined whether neutralization of IFN-α or IFN-γ in the sera altered the effect of the sera on liver-stage parasites. Either anti-IFN-α or anti-IFN-γ antibody was incubated with 100 μl of the sera, which contained 8,619 pg/ml of IFN-α and 4,705 pg/ml of IFN-γ. Complete neutralization of IFN-α was confirmed by ELISA (Figure 14B). The IFN-α- or IFN-γ-neutralized sera (100 μl) were intravenously administered to recipient mice that had been intravenously 24 h previously injected with 1,000 sporozoites. The anti-IFN-α antibody treatment completely abrogated the serum-induced delay of parasitaemia, whereas the anti-IFN-γ antibody treatment only partially impaired the serum-induced elimination effect (Figure 14A). These data suggest that the IFN-γ-mediated killing may be mediated via an effector mechanism distinct from that activated by IFN-α. It is possible that the effector mechanism induced by IFN-α and IFN-γ might still have been synergistically operative but that an alternate protective mechanism(s) may be activated with BV.

Figure 14: IFN-α induced by BV intramuscular administration contributes to elimination of liver-stage parasites. Results of a serum transfer assay to determine the role of IFN-α and IFN-γ in the elimination of liver-stage parasites (**A**). Sera collected from mice at 6 h after BV administration was neutralized by either anti-IFN-α or anti-IFN-γ antibody. Passive transfer of antibody-treated sera, non-treated sera, or PBS was conducted at 24 h after sporozoite infection (n = 5). The difference from the PBS group was assessed by a Kruskal-Wallis test with Dunn's correction. *$p < 0.05$, ***$p < 0.001$. Neutralization of IFN-α in sera from BV-administered mice (**B**). Aliquots of pooled sera from five BV-administered mice were neutralized by anti-IFN-α or anti-IFN-γ antibody. Complete neutralization of IFN-α was assessed by ELISA. Ab, antibody.

Role of exogenous IFNs in the elimination of liver-stage parasites

To assess the effects of exogenous IFN-α and IFN-γ on the elimination of liver-stage parasites, recombinant IFN-α (8,619 pg/mouse) or recombinant IFN-γ (4,705 pg/mouse) was intravenously administered to mice that had been intravenously injected 24 h before with 1,000 sporozoites. IFN-α administration eliminated the liver-stage parasites completely, whereas IFN-γ administration only partially eliminated them but caused a significant delay in the time to 1% parasitaemia (mean delay of 3.82 days; $p = 0.0082$, compared with the PBS group) (Figure 15). The IFN-α-mediated parasite elimination may be occur via an effector mechanism distinct from that activated by IFN-γ. It is also possible that the effector mechanisms induced by IFN-α and IFN-γ may still be synergistically operative but that an alternate protective mechanism may be activated by BV. Miller *et al.* similarly showed that IFN-γ produced by NKT cells following type I IFN signalling from infected hepatocytes play an important role in the elimination of liver-stage parasites (41). Result suggests that, the IFN-α-mediated parasite elimination may be mediated via an effector mechanism distinct from that activated by IFN-γ. Table 4 summarizes the results on the elimination efficacy against liver-stage parasites of serum transfer and IFN administration.

Figure 15: Effect of exogenous IFN-α or IFN-γ on the elimination of liver-stage parasites. Recombinant mouse IFN-α or IFN-γ was intravenously administered at 24 h after sporozoite infection (n = 5). The difference from the PBS group was assessed by a Kruskal-Wallis test with Dunn's correction. **$p < 0.01$.

Table 4. Elimination of liver-stage parasites by serum transfer and IFNs[a,b]

Treatment[a]	Dose	%Elimination (uninfected/total)	Days to 1% parasitaemia (p value compared with PBS control group)
Data from Fig. 14A[b]			
PBS sera	100 µl	0 (0/5)	6.03 ± 0.08
BV sera	100 µl	20 (1/5)	9.57 ± 0.38 ($p = 0.0008$)[c]
BV sera treated with anti-IFN-α antibody	100 µl	0 (0/5)	6.18 ± 0.16 ($p > 0.999$)
BV sera treated with anti-IFN-γ antibody	100 µl	0 (0/5)	7.59 ± 0.20 ($p = 0.0288$)[c]
Data from Fig. 15[b]			
PBS	100 µl	0 (0/5)	6.46 ± 0.13
BV sera	100 µl	20 (1/5)	10.02 ± 0.14 ($p = 0.0075$)[c]
Recombinant IFN-α	8,619 pg	100 (5/5)	-
Recombinant IFN-γ	4,705 pg	20 (1/5)	10.28 ± 0.41 ($p = 0.0082$)[c]

[a]BALB/c mice were intravenously injected with 1,000 Pb-conGFP sporozoites. After 24 h, mice were treated as indicated. Parasitaemia was monitored on days 5-11, and 14 after sporozoite injection. Once parasites appeared in the blood, all mice died.

[b]Schemes of the experimental designs are shown in Figure 19, C and D.

[c]Significant delay of parasitaemia was observed in infected mice, compared with the PBS control group by Kruskal-Wallis test.

IFN-stimulated genes (ISGs) are upregulated in the liver after BV intramuscular administration

Signal transduction of type I IFNs results in the induction of numerous ISGs (55). Some ISGs participate in direct antimicrobial activities, such as apoptosis induction and post-transcriptional event regulation of microbial killing, mainly acting as antiviral responses. Gene-targeting studies have distinguished four effector pathways of the IFN-mediated antiviral response: the Mx GTPase pathway, 2′-5′ oligoadenylate-synthetase (OAS)-directed ribonuclease L pathway, protein kinase R (PKR) pathway, and ISG15 ubiquitin-like pathway (56). Additionally, several ISGs, such as IFN-induced proteins with tetratricopeptide repeats

(IFITs), as well as the transcription factors IRF3 and IRF7 are responsible for sensing the liver-infection by *Plasmodium* sporozoites (13). To confirm the involvement of ISGs, the gene expression levels in the livers of mice that had been intramuscularly injected with BES-GL3 were measured by quantitative RT-PCR (qRT-PCR). BES-GL3 significantly induced the gene expression of several antiviral proteins (*Isg15, Mx1, Oas1a/b, Oasl1*, and *Pkr*) in WT mice (Figure 16). All these genes, except Oas1a/b, possibly due to the gene locus, were also upregulated by BV in *TLR9*[-/-] mice.

Figure 16: ISG induction in the liver after BV intramuscular administration. Gene expression of antiviral proteins in the livers of WT and *TLR9*[-/-] mice at 6 h after intramuscular administration of BES-GL3 (described as BV) (10^8 pfu) was measured by real-time RT-PCR (n = 5-7). Bars show means ± SEM. The difference from the PBS group was assessed by a Mann-Whitney's U test. *$p < 0.05$, **$p < 0.01$.

Recent study demonstrated that similar subsets of ISGs such as *Ifit1*, *Ifit3,* and *Ifit44* were upregulated by *Plasmodium* liver-stage infection as a type I IFN response (13). In my study, the expression levels of such genes were significantly induced by the immunization of BES-GL3 with much higher extent than that by *Plasmodium* infection (Figure 17). Consistent with the profile of other ISGs, *Ifit1*, *Ifit3,* and *Ifit44* were upregulated in *TLR9*[-/-] mice immunized with BES-GL3 (Figure 17).

Figure 17: BV intramuscular administration induces IFITs in the liver. Gene expression of IFITs in the livers of WT and *TLR9$^{-/-}$* mice at 6 h after intramuscular administration of BES-GL3 (described as BV) (10^8 pfu) was measured by real-time RT-PCR (n = 5-7). Bars show means ± SEM. The difference from the PBS group was assessed by a Mann-Whitney's U test. **p < 0.01.

Expressions of type I IFNs after the microbial recognition were regulated by two transcription factors, interferon regulatory factor (IRF) IRF3 and IRF7. Interestingly, the expression levels of IRF3 and IRF7 were significantly enhanced in the liver, far from the injection site, after the immunization of BES-GL3 (Figure 18); the high expression of the transcription factors might further enhance the autocrine/paracrine-gene expression during a type I IFN-signaling pathway. Regardless of the TLR9-signaling pathway, the expressions of IRF3/7 were induced by BES-immunization (Figure 18). These results indicate that systemic type I IFN secretion following BV intramuscular administration in the thigh muscle strongly induced ISGs in the liver.

Figure 18: BV intramuscular administration induces IRFs in the liver. Gene expression of IRFs in the livers of WT and *TLR9[-/-]* mice at 6 h after intramuscular administration of BES-GL3 (described as BV) (10^8 pfu) was measured by real-time RT-PCR (n = 5-7). Bars show means ± SEM. The difference from the PBS group was assessed by a Mann-Whitney's U test. *$p < 0.05$.

An AdHu5-prime/BDES-boost heterologous immunization regimen confers sterile protection and complete elimination

To evaluate our previously developed malaria vaccine in an AdHu5-prime/BDES-boost heterologous immunization regimen (19), mice were challenged twice, once before and once after the BDES-PfCSP-boost. All the fully immunized mice were protected against both the first and second challenges (Table 5, Group 2). In contrast, AdHu5-prime immunization alone did not confer protection (Group 1). Although BES-GL3 intravenous administration completely eliminated the liver-stage parasites (Group 4), there was no protection against 2nd challenge 21 days after 1st challenge. All control mice intramuscularly injected with PBS became infected (Groups 3 and 5). Thus, BDES-PfCSP boosting was able to exert not only a therapeutic effect on liver-stage parasites but also a prophylactic effect on sporozoites. These results indicate that AdHu5-prime/BDES-boost heterologous immunization regimen eliminates the liver-stage parasites by BV-mediated innate immune responses and protects against challenge by vaccine-specific adaptive immune responses. The animal experimental designs are illustrated in Figure 19, E and F.

Table 5: Elimination and protective efficacy of AdHu5-prime/BDES-boost heterologous immunization regimen[a]

Group	Prime	Boost	Time interval of 1st sporozoite challenge	%Protection (protection/total)	Time interval of 2nd sporozoite challenge	%Protection (protection/total)
1[b]	AdHu5-sPfCSP2	PBS	24 h before boost	0 (0/5)	-	-
2[c]	AdHu5-sPfCSP2	BDES-sPfCSP2	24 h before boost	100 (5/5)	21 d after 1st sporozoite challenge	100 (5/5)
3[d]	PBS	PBS	24 h before boost	0 (0/10)	-	-
4[e]	-	BV	6 h before challenge	100 (8/8)	21 d after 1st sporozoite challenge	0 (0/8)
5[f]	PBS	PBS	21 d after boost	0 (0/5)	-	-

[a]Schemes of the experimental designs are shown in Figure 19, E and F.

[b]BALB/c mice were intramuscularly immunized with AdHu5-PfCSP (described as AdHu5). After 3 weeks, mice were intramuscularly injected with PBS 24 h following intravenously injected with 1,000 1,000 PfCSP-Tc/Pb sporozoites. Parasitaemia was monitored on days 5, 6, 7, 8, 11, and 14 after sporozoite injection. Once parasites appeared in the blood, all mice died.

[c]BALB/c mice were intramuscularly immunized with AdHu5. After 3 weeks, mice were intramuscularly injected with BDES-PfCSP (described as BDES) 24 h following intravenously injected with 1,000 PfCSP-Tc/Pb sporozoites. Protected mice were 2nd-challenged 21 days after 1st challenge.

[d]BALB/c mice were intramuscularly immunized with PBS. After 3 weeks, mice were intramuscularly injected with PBS 24 h following intravenously injected with 1,000 PfCSP-Tc/Pb sporozoites. The group 3 was used as a control infection for 1st challenge of the groups 1 and 2.

[e]BALB/c mice were intravenously immunized with BES-GL3 (described as BV). After 6 h, mice were intravenously challenged with 1,000 PfCSP-Tc/Pb sporozoites. Protected mice were 2nd-challenged 21 days after 1st challenge.

[f]BALB/c mice were intramuscularly immunized with PBS twice at day 0 and 21. After 3 weeks, mice were intravenously challenged with 1,000 PfCSP-Tc/Pb sporozoites. The group 5 was used as a control challenge for 2nd challenge of the group 4.

Experimental design

The clinically silent pre-erythrocytic stages of mammalian *Plasmodium* spp, composed of both the sporozoite and liver stages are ideal targets for vaccine interventions and prophylactic drug discovery. Because if infection is blocked at these stages, there will be no subsequence blood-stage parasites and therefore neither clinical symptom nor transmission. My present study aim to assessed the capability of the BV-induced innate immune responses to protect mice against malaria pre-erythrocytic stage. My main focus was to target the *Plasmodium* parasites that reach the liver and invade hepatocytes to ultimately prevent the release of merozoites that will infect red blood cells. The experimental design are shown in Figure 19.

A, BV administration before spz infection

B, BV administration after spz infection

C, Serum transfer after spz infection

D, IFNs administration after spz infection

E, AdHu5-immunization before spz infection

F, AdHu5-prime/BDES-boost heterologous immunization, spz infection before and after BDES-boost immunization

Figure 19: Experimental design. Mice were intravenously, intramuscularly, or intranasally administered BES-GL3 (described as BV) or CpG followed by an intravenous challenge with 1,000 Pb-conGFP sporozoites or 1,000 iRBC at various time intervals (6 h–14 days). The results are shown in Table 1 (**A**). Mice were intravenously injected with 1,000 Pb-conGFP sporozoites. At 24 or 42 h after liver-stage development, the mice were injected with either BV, CpG, or PQ. The results are shown in Table 2 and 3 (**B**). Pooled sera were obtained from donor mice that had been intramuscularly injected with BV 6 h before. Recipient mice were intravenously injected with 1,000 Pb-conGFP sporozoites. After 24 h, the recipient mice were intravenously injected with either non- treated pooled sera or pooled sera that had been treated with anti-IFN-α, or anti-IFN-γ antibody. The results are shown in Figure 14A (**C**). Mice were intravenously injected with 1,000 Pb-conGFP sporozoites. At 24 h after liver-stage development, the mice were intravenously injected with either IFN-α or IFN-γ. The results are shown in Figure 15 (**D**). Mice were intramuscularly immunized with an AdHu5-prime and PBS-boost regimen with a 3-weeks interval. The mice were intravenously challenged with 1,000 PfCSP-Tc/Pb sporozoites at 24 h before PBS boosting. The results are shown in Table 5 (**E**). Mice were intramuscularly immunized with a heterologous AdHu5-prime and BDES-boost regimen with a 3-weeks interval. The mice were intravenously challenged with 1,000 PfCSP- Tc/Pb sporozoites at 24 h before BDES boosting (first challenge). Protected mice were re- challenged in the same manner at 21 days after the first challenge. The results are shown in Table 5 (**F**). Spz, sporozoites.

DISCUSSION

Before the clinical phase of malaria infection in blood stage, *Plasmodium* sporozoite parasites, injected by a female *Anopheles* mosquito, travel to the liver and infect hepatocytes. The liver-stage parasites asymptomatically produce thousands of merozoites that will subsequently infect erythrocytes. Therefore, effective innate immune responses raised before or during the liver-stage infection could prevent the onset of disease. In this study, I focused on characteristics features of BV with activation of innate immunity. The aim of my study was to assess the capability of the BV-induced innate immune responses for protecting mice against malaria pre-erythrocytic stage along with its adjuvant properties. Here I demonstrate that BV intramuscular administration not only elicits short-term sterile protection against sporozoite infection but also eliminates liver-stage parasites completely.

Probable mechanisms for complete elimination of liver-stage parasites by baculovirus

This study showed that IFN-α and IFN-γ were rapidly and robustly produced in serum at 6 h post-BV intramuscular administration in a TLR9-independent manner and upregulates ISGs expression in the liver. In addition, in vivo passive transfer of the serum effectively eliminated liver-stage parasites that were fully abolished by neutralization of IFN-α. This result was consistent with the finding that intravenous administration of IFN-α completely eliminated the liver-stage parasites. Thus, I observed that type I IFN signaling pathway play an important role in the killing mechanism of liver-stage parasites. Interestingly, the prophylactic effect against sporozoite infection persisted for at least 7 days, even though IFN-γ and TNF-α serum levels returned to baseline by 24 h. I speculate that the prophylactic effect at day 7 post-BV administration may be due to the killing of parasites in the liver rather than to an invasion blockade mediated by serum components. In the case of 'natural' *Plasmodium* liver-stage infection, the infected hepatocytes induce IFN-α, resulting in a reduction of the liver-stage burden (13). However, the parasite-induced IFN-α responses fail to eliminate every parasite. This implies that the endogenous innate immune responses may be not strong enough for complete elimination and/or that the innate immune response peak occurs at the end of liver-stage development, just prior to or concurrent with exoerythrocytic merozoites release (57). Otherwise, the parasite has probably devised strategies to counteract it, eg., inhibition of apoptotic pathways of the host hepatocyte to ensure their own survival (57). Compared with the type I IFN induced by host sensing of parasites, the quantity of BV-induced type I IFN and its speedy induction may make it more effective, resulting in its

potent therapeutic and prophylactic effects. My results are consistent with recent data from Liehl *et al*. reporting that the ISGs induced in infected hepatocytes by a high dose of sporozoites reduced the liver-stage burden (13). Collectively, these data suggest that the innate immune responses induced by intramuscular injection of BV comprise not only IFN production but also activation of an unknown pathway(s) in the liver and that BV injection induces these more rapidly and effectively than does sporozoite infection.

Gronowski *et al*. initially demonstrated that BV induced type I IFN from murine and human cell lines and conferred in vivo protection of mice from encephalomyocarditis virus infection (58). Recently, Ono *et al*. reported that after being transduced, the host cells senses BV genomic dsDNA via the cytosolic DNA sensor STING recognition, resulting in the production of type I IFN in response to BV transduction via TLR9-independent pathway (59). Abe *et al*. also demonstrate the BV-induced type I IFN is TLR9-dependent and -independent pathways (14). Zheng *et al*. showed that TLR2 but not other TLRs is involved in recognition of invading sporozoites and initiate innate immune responses against intrahepatic parasites (60). The produced type-I IFNs alert the surrounding cells by triggering signaling cascades that lead to phosphorylation and nuclear translocation of STAT1 (60). Hervas-Stubbs *et al*. also showed that BVs have strong adjuvant properties, promoting humoral and CTL responses against the coadministered antigen, DC maturation, and the production of inflammatory mediators through mechanisms primarily mediated by type-I IFN (61).

However, the precise mechanisms by which BV activates STING in vivo remain unclear. Type I IFNs can also be induced by host factors and cytokines such as TNF, which signal via IFN-regulatory factor 1 (IRF1) rather than via IRF3 and IRF7, and by macrophage colony stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL) (62). Contrarily, IFN-γ plays an important role in the elimination of liver-stage *Plasmodium* parasites, but the mechanism involved in this process is unclear. Additional in vivo study validated the importance of IFN-γ in protective immunity as it inhibits intracellular development of parasite within hepatocytes following challenge with *P. berghei* (10), *P. yoelii* (63), or *P. vivax* sporozoites (11) in mice and chimpanzee, respectively. Recently, Miller *et al*. demonstrated that IFN-γ secreted in primary *P. yoelii* sporozoite infection is the key innate mediator that controls liver-stage parasite growth in a secondary infection (41). More recently, Lelliott and Coban remarked that IFN-γ protects hepatocytes against *P. vivax* infection via LAP-like degradation of sporozoites (64). In contrast to that report, the present study shows that substantial amount of IFN-γ in sera induced by intramuscular BV

administration had little effect on the parasite elimination in vivo. My results on IFN-α and IFN-γ suggest that IFN-α stimulation quickly activates downstream of its signaling pathway, compared with IFN-γ stimulation, and in vivo IFN-γ stimulated parasite killing in the liver may require much higher concentration of IFN-γ (400 U IFN-γ/mL) against much earlier liver-stage parasites (4 h after infection). For vaccine development against the pre-erythrocytic stage, it has been widely accepted that an ideal vaccine should induce IFN-γ-mediated cellular immune responses.

The present study showed that IFN-α, TNF-α, and IFN-γ were rapidly and robustly produced in serum 6 h following BV administration. Consistent with my data, Nishibe *et al*. reported that intraperitoneal BV administration alleviates dimethylnitrosamine-induced liver cirrhosis symptoms through type I and II IFNs in a murine model (65). Remarkably, there are ~300 interferon-stimulated genes which are linked to the type I IFN signaling pathway (55, 66, 67). *Isg15, Mx1, OAS1, OASL,* and *PKR* genes, which are well-known as antiviral effectors (56), were up-regulated in the hepatocytes by BV intramuscular administration. It is also of interest to explore cross-regulations between type I and II IFNs for signaling into infected hepatocytes and Kupper cells. A better understanding of the molecular mechanisms by which BV administration confers both protection and elimination of pre-erythrocytic parasites will provide new strategies for malaria drug and vaccine development.

Application in drug development

For liver-stage parasites proliferating vigorously at 24 h post-infection, the BV-induced fast-acting innate immune responses completely killed them within the following 20 h and prevent blood-stage parasite development in the absence of any clinical symptoms, which is more effective than PQ in a mouse model with early liver-stage *P. berghei*. A major challenge for strategies combating the human malaria parasite *P. vivax* is the presence of hypnozoites in the liver. PQ is currently the only available drug that kills the dormant hypnozoites of *P. vivax*, but its severe side effects in G6PD-deficient people prevent the widespread use of this drug (68). The *P. berghei* liver-stage model is thought to correlate with anti-hypnozoite activity in primates (69). The presence of hypnozoites and their drug-insensitivity form a major hurdle for malaria elimination programmes, and it is generally agreed that the mission to eradicate malaria initiated by Bill and Melinda Gates (70) can only be successful if effective means exist to remove this hidden reservoir of hypnozoites from the population (71, 72). The present study shows that BV is more effective than PQ in a mouse

model with early liver-stage *P. berghei,* which is thought to correlate with anti-hypnozoite activity in primates (69). To date, the closely related malaria parasite *P. cynomolgi*, which infects non-human primates, has been the gold-standard in vivo model for studying hypnozoites (73). Although *P. berghei* does not have a dormant hypnozoite stage, it is possible that the therapeutic effect of BV against liver-stage infection may provide clues on how to eliminate hypnozoites. Further experiments in the *P. cynomolgi* model are needed to evaluate the potential of BV as a new non-haemolytic single-dose alternative to PQ. Thus, BV offers a promising new non-haemolytic single-dose alternative to PQ for first-in-human clinical trials. Further experiments to determine optimum BV administration routes and dosages are needed.

Application in vaccine development

BV possesses attractive attributes as a new vaccine vector, including its low cytotoxicity, inability to replicate in mammalian cells, absence of pre-existing antibodies against it, display of the vaccine antigen on the viral envelope with near-naïve form (known as "baculophage"), transduction of mammalian cells (known as "BacMam"), and function as both a vaccine component and a DNA vaccine (known as "baculovirus dual-expression system-BDES") (17). This study suggests a further unique advantage of BV as a vaccine additive with short-term protection against malaria via its intrinsic potent immunostimulatory property. Generally, adaptive immunity induced by vaccines takes several days to become effective and often requires two or three doses. Even effective licensed vaccines cannot protect individuals from the target pathogen immediately after vaccination. Therefore, in addition to long-term protective immunity, it is ideal that a next-generation vaccine could induce effective short-term non-specific immunity to minimize the risk of infection during the vaccination schedule. In a Phase II–III malaria vaccine trials, all volunteers are presumptively treated with three daily doses of anti-malaria drug for one week before the final vaccination and rechecked for asexual *P. falciparum* parasitaemia at one week after the final vaccination. Any subject who tests parasite-positive is treated with a second line drug or excluded from the trial (74). Thus, clinical trials aim to test vaccine efficacy after all vaccine schedules are completed to assess the maximum effect. For clinical application, however, vaccine recipients remain in danger of infection until the full vaccination schedule is completed, even though improved effective vaccine would be developed. If BV was co-administered as an additive with a newly developed malaria vaccine like RTS,S, the joint vaccine would be expected to not only minimize the risk of infection for vaccine recipients

during the vaccination schedule but also generate robust and long-lasting adaptive immune responses via innate immune system stimulation by BV acting as an adjuvant. Our previous study showed that repeated administration of BV reduces its transduction efficacy by antibody-mediated neutralization (23). Further studies are needed to address whether the induction of innate immune responses by BV is linked to its transduction efficacy. This study also shows that our newly developed heterologous AdHu5-PfCSP-prime and BDES-PfCSP-boost vaccine eliminated liver-stage parasites that had infected the mice 24 h before administration of the BDES-boost and also elicited sterile protection against sporozoite challenge 21 days post-boost. We propose that BV-based vaccines can not only minimize the risk of infection for vaccinators during the vaccination schedule but also generate robust and long-lasting adaptive immune responses via stimulation of the innate immune system. Alternatively, BV itself may also be used as an additive to eliminate liver-stage parasites and impart this short-term protection to RTS,S or other licensed vaccines.

Application in IFN-α immunotherapy

IFN-α has been extensively explored for its efficacy in various disease conditions and is currently used as a standard treatment in several illnesses, especially chronic hepatitis C (HCV) for which IFN-α has been used as the only approved treatment since 1991. However, its use is accompanied by a wide variety of possible side effects (75), such as autoimmune thyroiditis. Moreover, the standard treatment of HCV with IFN-α and ribavirin can cost an average of US$22,000, and, depending on genotype, as few as 42% of treated individuals subsequently clear the infection (76).

I found that BV intramuscular administration, which induced 8,619 pg/ml of IFN-α in mouse sera while maintaining normal ALT levels, completely killed liver-stage parasites. The manufacturing cost of BV would be much lower than that of rIFN-α. Thus, BV intramuscular administration also has great potential for use as an alternative IFN-α-based immunotherapy; its high biological activity, cost-effectiveness, non-invasive nature, and minimal adverse effects make it superior to the current IFN-α therapy using recombinant IFN-α via intravenous administration. Although the present study consistently used a DAF-shielded BES-GL3 to monitor transgene expression in the liver and muscle, WT AcNPV should exert the same function as BES-GL3 in terms of IFN-α production and anti-parasite effects. Future work should investigate whether other Baculoviridae family members can induce more effective killing of liver-stage parasites.

In conclusion, BV effectively induces fast-acting innate immune responses that provide powerful first lines of both defensive and offensive attacks against pre-erythrocytic parasites. My results illustrate the potential of BV as a new potent prophylactic and therapeutic immunostimulatory agent against pre-erythrocytic-stage parasites. Even though the First-in-Human trials of BV have not yet been conducted, our previous study showed that the BV-based vaccine vector is safe and well-tolerated with acceptable reactogenicity and systemic toxicity in a primate model (18). In addition, the BV system itself has proven to be clinically suitable and has been approved for the purposes of vaccination. BV-based vaccines include Cervarix (GlaxoSmithKline, Rixensart, Belgium), a human papillomavirus (strain 16 and 18) viral-like particle vaccine against cervical cancer, and Provenge (Dendreon Inc., Seattle, USA), which is an immune-therapeutic vaccine against prostate cancer. Although further studies are needed to clarify the prophylactic and therapeutic effects of BV in a non-human primate malaria model (e.g. doses and repeated treatment), our results highlight useful characteristics of BV that may pave the way for developing new malaria drug and vaccine strategies.

REFERENCES

1. WHO (2016) World Malaria Report 2016. *World Malaria Report 2016*.

2. Williams CT & Azad AF (2010) Transcriptional analysis of the pre-erythrocytic stages of the rodent malaria parasite, *Plasmodium yoelii. PLoS One* 5(4):e10267.

3. WHO (2012) World malaria report 2012.

4. Ajayi NA & Ukwaja KN (2013) Possible artemisinin-based combination therapy-resistant malaria in Nigeria: a report of three cases. *Rev Soc Bras Med Trop* 46(4):525-527.

5. (WHO) WHO (Update on artemisinin resistance - April 2012. Geneva: WHO; 2012. [Cited 2013 May 24]

6. Edgcomb JH*, et al.* (1950) Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report. *J Natl Malar Soc* 9(4):285-292.

7. White NJ (2004) Antimalarial drug resistance. *J Clin Investig* 113(8):1084-1092.

8. Vergara U, Ferreira A, Schellekens H, & Nussenzweig V (1987) Mechanism of escape of exoerythrocytic forms (EEF) of malaria parasites from the inhibitory effects of interferon-gamma. *J Immunol* 138(12):4447-4449.

9. Schofield L, Ferreira A, Altszuler R, Nussenzweig V, & Nussenzweig RS (1987) Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. *J Immunol* 139(6):2020-2025.

10. Schofield L*, et al.* (1987) Gamma interferon, CD8[+] T cells and antibodies required for immunity to malaria sporozoites. *Nature* 330(6149):664-666.

11. Ferreira A*, et al.* (1986) Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. *Science* 232(4752):881-884.

12. Boonhok R*, et al.* (2016) LAP-like process as an immune mechanism downstream of IFN-gamma in control of the human malaria *Plasmodium vivax* liver stage. *Proc Natl Acad Sci USA* 113(25):E3519-3528.

13. Liehl P*, et al.* (2014) Host-cell sensors for *Plasmodium* activate innate immunity against liver-stage infection. *Nat Med* 20(1):47-53.

14. Abe T*, et al.* (2009) Baculovirus induces type I interferon production through toll-like receptor-dependent and -independent pathways in a cell-type-specific manner. *J Virol* 83(15):7629-7640.

15. Moriyama T, Suzuki T, Chang MO, Kitajima M, & Takaku H (2017) Baculovirus directly activates murine NK cells via TLR9. *Cancer Gene Ther* 24(4):175-179.

16. Kitajima M*, et al.* (2008) Induction of natural killer cell-dependent antitumor immunity by the *Autographa californica* multiple nuclear polyhedrosis virus. *Mol Ther* 16(2):261-268.

17. Yoshida S, Kawasaki M, Hariguchi N, Hirota K, & Matsumoto M (2009) A baculovirus dual expression system-based malaria vaccine induces strong protection against *Plasmodium berghei* sporozoite challenge in mice. *Infect Immun* 77(5):1782-1789.

18. Iyori M*, et al.* (2013) Protective efficacy of baculovirus dual expression system vaccine expressing *Plasmodium falciparum* circumsporozoite protein. *PLoS One* 8(8):e70819.

19. Yoshida K*, et al.* (2018) Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model. *Sci Rep* 8(1):3896.

20. Yoshida S, Araki H, & Yokomine T (2010) Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice. *Infect Immun* 78(2):595-602.

21. Yoshida S*, et al.* (2010) *Plasmodium berghei* circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines. *PLoS One* 5(10):e13727.

22. Mlambo G, Kumar N, & Yoshida S (2010) Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen. *Vaccine* 28(43):7025-7029.

23. Blagborough AM, Yoshida S, Sattabongkot J, Tsuboi T, & Sinden RE (2010) Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks *Plasmodium vivax* transmission. *Vaccine* 28(37):6014-6020.

24. Yamamoto DS, Sumitani M, Nagumo H, Yoshida S, & Matsuoka H (2012) Induction of antisporozoite antibodies by biting of transgenic *Anopheles stephensi* delivering malarial antigen via blood feeding. *Insect Mol Biol* 21(2):223-233.

25. Franke-Fayard B*, et al.* (2004) A *Plasmodium berghei* reference line that constitutively expresses GFP at a high level throughout the complete life cycle. *Mol Biochem Parasitol* 137(1):23-33.

26. Matsuoka H, Tomita H, Hattori R, Arai M, & Hirai M (2015) Visualization of malaria parasites in the skin using the luciferase transgenic parasite, *Plasmodium berghei*. *Trop Med Health* 43(1):53-61.

27. Sumitani M*, et al.* (2013) Reduction of malaria transmission by transgenic mosquitoes expressing an antisporozoite antibody in their salivary glands. *Insect Mol Biol* 22(1):41-51.

28. Longley RJ*, et al.* (2015) Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. *Sci Rep* 5:11820.

29. Iyori M*, et al.* (2017) DAF-shielded baculovirus-vectored vaccine enhances protection against malaria sporozoite challenge in mice. *Malar J* 16(1):390.

30. Yoshida K*, et al.* (2018) Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model. *Sci Rep* 8(1):3896.

31. Epstein JE*, et al.* (2011) Live attenuated malaria vaccine designed to protect through hepatic CD8[+] T cell immunity. *Science* 334(6055):475-480.

32. Franke-Fayard B, Waters AP, & Janse CJ (2006) Real-time in vivo imaging of transgenic bioluminescent blood stages of rodent malaria parasites in mice. *Nature Protoc* 1(1):476-485.

33. Matsuoka H, Tomita H, Hattori R, Arai M, & Hirai M (2015) Visualization of malaria parasites in the skin using the luciferase transgenic parasite, *Plasmodium berghei*. *Trop Med Health* 43(1):53-61.

34. Yamamoto DS*, et al.* (2013) Visualization and live imaging analysis of a mosquito saliva protein in host animal skin using a transgenic mosquito with a secreted luciferase reporter system. *Insect Mol Biol* 22(6):685-693.

35. Miller LK (1988) Baculoviruses as gene expression vectors. *Annu Rev Microbiol* 42:177-199.

36. Kidd IM & Emery VC (1993) The use of baculoviruses as expression vectors. *Appl Biochem Biotechnol* 42(2-3):137-159.

37. Luo WY*, et al.* (2013) Adaptive immune responses elicited by baculovirus and impacts on subsequent transgene expression in vivo. *J Virol* 87(9):4965-4973.

38. Hofmann C*, et al.* (1995) Efficient gene transfer into human hepatocytes by baculovirus vectors. *Proc Natl Acad Sci USA* 92(22):10099-10103.

39. Hofmann C & Strauss M (1998) Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. *Gene Ther* 5(4):531-536.

40. Yoshida S*, et al.* (2003) Baculovirus virions displaying *Plasmodium berghei* circumsporozoite protein protect mice against malaria sporozoite infection. *Virology* 316(1):161-170.

41. Miller JL, Sack BK, Baldwin M, Vaughan AM, & Kappe SH (2014) Interferon-mediated innate immune responses against malaria parasite liver stages. *Cell Rep* 7(2):436-447.

42. Krieg AM (2003) CpG motifs: the active ingredient in bacterial extracts? *Nat Med* 9(7):831-835.

43. Gramzinski RA*, et al.* (2001) Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. *Infect Immun* 69(3):1643-1649.

44. Krug A*, et al.* (2001) Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. *Eur J Immunol* 31(7):2154-2163.

45. Suzuki T, Chang MO, Kitajima M, & Takaku H (2010) Baculovirus activates murine dendritic cells and induces non-specific NK cell and T cell immune responses. *Cell Immunol* 262(1):35-43.

46. Krieg AM, Hartmann G, & Yi AK (2000) Mechanism of action of CpG DNA. *Curr Top Microbiol Immunol* 247:1-21.

47. Haque A*, et al.* (2011) High parasite burdens cause liver damage in mice following *Plasmodium berghei* ANKA infection independently of CD8(+) T cell-mediated immune pathology. *Infect Immun* 79(5):1882-1888.

48. Adachi K*, et al.* (2001) *Plasmodium berghei* infection in mice induces liver injury by an IL-12- and toll-like receptor/myeloid differentiation factor 88-dependent mechanism. *J Immunol* 167(10):5928-5934.

49. Abe T*, et al.* (2005) Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus. *J Virol* 79(5):2847-2858.

50. Collins WE & Jeffery GM (1996) Primaquine resistance in *Plasmodium vivax*. *Am J Trop Med Hyg* 55(3):243-249.

51. Baird JK (2009) Resistance to therapies for infection by *Plasmodium vivax*. *Clin Microbiol Rev* 22(3):508-534.

52. Garnham PC (1980) Malaria in its various vertebrate hosts. *In J. P. Kreier (ed.), Malaria, vol. 1. Epidemiology, Chemotherapy, Morphology, and Metabolism. Academic Press, Inc., New York*:96-144.

53. Kawabata T*, et al.* (2008) Functional alterations of liver innate immunity of mice with aging in response to CpG-oligodeoxynucleotide. *Hepatology* 48(5):1586-1597.

54. Sparwasser T*, et al.* (1999) Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. *J Immunol* 162(4):2368-2374.

55. Der SD, Zhou A, Williams BR, & Silverman RH (1998) Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. *Proc Natl Acad Sci USA* 95(26):15623-15628.

56. Sadler AJ & Williams BR (2008) Interferon-inducible antiviral effectors. *Nat Rev Immunol* 8(7):559-568.

57. van de Sand C*, et al.* (2005) The liver stage of *Plasmodium berghei* inhibits host cell apoptosis. *Mol Microbiol* 58(3):731-742.

58. Gronowski AM, Hilbert DM, Sheehan KC, Garotta G, & Schreiber RD (1999) Baculovirus stimulates antiviral effects in mammalian cells. *J Virol* 73(12):9944-9951.

59. Ono C*, et al.* (2014) Innate immune response induced by baculovirus attenuates transgene expression in mammalian cells. *J Virol* 88(4):2157-2167.

60. Zheng H*, et al.* (2015) The TLR2 is activated by sporozoites and suppresses intrahepatic rodent malaria parasite development. *Sci Rep* 5:18239.

61. Hervas-Stubbs S, Rueda P, Lopez L, & Leclerc C (2007) Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. *J Immunol* 178(4):2361-2369.

62. Yarilina A & Ivashkiv LB (2010) Type I interferon: a new player in TNF signaling. *Curr Dir Autoimmun* 11:94-104.

63. Nussler AK*, et al.* (1993) In vivo induction of the nitric oxide pathway in hepatocytes after injection with irradiated malaria sporozoites, malaria blood parasites or adjuvants. *European J Immunol* 23(4):882-887.

64. Lelliott PM & Coban C (2016) IFN-γ protects hepatocytes against *Plasmodium vivax* infection via LAP-like degradation of sporozoites. *Proc Natl Acad Sci USA* 113(25):6813-6815.

65. Nishibe Y, *et al.* (2008) Baculovirus-mediated interferon alleviates dimethylnitrosamine-induced liver cirrhosis symptoms in a murine model. *Gene Ther* 15(13):990-997.

66. Schoggins JW & Rice CM (2011) Interferon-stimulated genes and their antiviral effector functions. *Curr Opin Virol* 1(6):519-525.

67. de Veer MJ, *et al.* (2001) Functional classification of interferon-stimulated genes identified using microarrays. *J Leukoc Biol* 69(6):912-920.

68. Clyde DF (1981) Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. *Bull World Health Organ* 59:391-395.

69. Fracisco S, *et al.* (2014) Anti-relapse activity of mirincamycin in the *Plasmodium cynomolgi* sporozoite-infected Rhesus monkey model. *Malar J* 13:409.

70. Roberts L & Enserink M (2007) Malaria. Did they really say ... eradication? *Science* 318(5856):1544-1545.

71. Wells TN, Burrows JN, & Baird JK (2010) Targeting the hypnozoite reservoir of *Plasmodium vivax*: the hidden obstacle to malaria elimination. *Trends Parasitol* 26(3):145-151.

72. Mueller I, *et al.* (2009) Key gaps in the knowledge of *Plasmodium vivax*, a neglected human malaria parasite. *Lancet Infect Dis* 9(9):555-566.

73. Galinski MR & Barnwell JW (2008) *Plasmodium vivax*: who cares? *Malar J* 7 Suppl 1:S9.

74. Polhemus ME, *et al.* (2009) Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. *PLoS One* 4(7):e6465.

75. Sleijfer S, Bannink M, Van Gool AR, Kruit WH, & Stoter G (2005) Side effects of interferon-alpha therapy. *Pharm World & Sci: PWS* 27(6):423-431.

76. Lang K & Weiner DB (2008) Immunotherapy for HCV infection: next steps. *Expert Rev Vaccines* 7(7):915-923.